Wang K.-L.Chang T.-C.Jung S.-M.CHI-HAU CHENCheng Y.-M.Wu H.-H.Liou W.-S.Hsu S.-T.Ou Y.-C.Yeh L.-S.Lai H.-C.Huang C.-Y.Chen T.-C.Chang C.-J.Lai C.-H.2020-01-222020-01-222012https://scholars.lib.ntu.edu.tw/handle/123456789/452920Background: Our aims were to investigate the treatment and clinicopathological variables in relation to prognosis in small cell neuroendocrine cervical carcinoma (SCNECC). Patients and methods: Clinical data of SCNECC patients with International Federation of Gynaecology and Obstetrics (FIGO) stages I-IV treated between 1987 and 2009 at member hospitals of the Taiwanese Gynecologic Oncology Group (TGOG) were retrospectively reviewed. Results: Of the 179 eligible patients, 104 were of FIGO stage I, 19 stage IIA, 23 stage IIB, 9 stage III, and 24 stage IV. The median failure-free survival (FFS) was 16.0 months, and the median cancer-specific survival (CSS) was 24.8 months. In multivariate analysis, FIGO stage and lymph node metastasis were selected as independent variables in stages I-IV. In stages IIB-IVB, primary treatment containing etoposide and platinum for at least 5 cycles (EP5+) (n = 16) was associated with significantly better 5-year FFS (42.9% versus 11.8%, p = 0.041) and CSS (45.6% versus 17.1%, p = 0.035) compared to other treatments (n = 40). Furthermore, concurrent chemoradiation with EP5+ (CCRT-EP5+) was associated with even better 5-year FFS (62.5% versus 13.1%, p = 0.025) and CSS (75.0% versus 16.9%, p = 0.016). Conclusions: FIGO stage and lymph node metastasis are significant prognostic factors in SCNECC. In stages IIB-IVB, CCRT-EP5+ might be the treatment of choice, which could be also true for earlier stages. Despite limitations of a retrospective study spanning a long time period and heterogeneous managements, the results provide an important basis for designing future prospective studies. ? 2011 Elsevier Ltd. All rights reserved.[SDGs]SDG3etoposide; platinum; adult; article; cancer chemotherapy; cancer prognosis; cancer specific survival; cancer staging; cancer surgery; chemoradiotherapy; failure free survival; female; human; intermethod comparison; lymph node metastasis; major clinical study; neuroendocrine tumor; priority journal; small cell carcinoma; small cell neuroendocrine cervical carcinoma; Taiwan; treatment outcome; uterine cervix carcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Disease-Free Survival; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Registries; Retrospective Studies; Taiwan; Time Factors; Treatment Outcome; Uterine Cervical Neoplasmsjournal article10.1016/j.ejca.2011.12.0142-s2.0-84862819949